By clicking below you acknowledge that you are navigating away from temaetfs.com and will be connected to temafunds. Tema Global Limited manages both domains. Please tack note of Tema's privacy policy, terms of use, and disclosures that may vary between sites.
Invest directly by choosing one of the brokers below
Get in Touch
HRTS
Heart & Health ETF
Invest in GLP-1 & Chronic Disease Pioneers
Why Invest in HRTS?
Healthcare Growth Outlook
U.S. healthcare spending is forecast to reach $9 trillion by 2034,1 as chronic disease fuels demand for treatment
¹CMS, Jul 2026
Innovation
Offers a high-conviction portfolio across innovative biopharma, medical devices and healthcare services
Investment Expertise
Actively managed by a Yale- and Penn-trained physician turned veteran healthcare investor
Portfolio Highlights
Eli Lilly (LLY) is the developer of Mounjaro and Zepbound—among the world's most impactful medicines for type 2 diabetes and obesity—which also demonstrate meaningful cardiovascular risk reduction.
Kodiak Sciences (KOD) is developing long-acting therapies for diabetic retinopathy and macular degeneration, aiming to preserve vision while reducing the frequency of eye injections.
BridgeBio Pharma (BBIO) is the developer of Attruby, an approved treatment for a progressive heart condition caused by abnormal protein buildup.
Portfolio holdings are subject to change. Review current holdings below.
Fund Overview
Fund Details
As of October 29, 2026
Ticker
HRTS
CUSIP
87975E883
Inception Date
11/20/23
Gross Expense Ratio
0.99%
Net Expense Ratio*
0.75%
AUM
$57,099,488
Shares Outstanding
1,480,000
Number of Holdings
47
Primary Exchange
Nasdaq
Portfolio Manager
David K. Song, MD, PhD, CFA
*Contractual expense cap for net expense ratio of 0.75% is in effect through 06/28/2027.
Fund Summary
The Tema Heart & Health ETF (HRTS) invests in companies advancing prevention and treatment of chronic conditions, including heart disease, diabetes, and obesity.
Portfolio Breakdown
Top 10 Holdings
As of October 30, 2026
Company
% of Nav
ELI LILLY & CO
12.78%
THERMO FISHER SCIENTIFIC INC
5.06%
MERCK & CO INC
4.48%
ROCHE HOLDING AG
4.39%
KODIAK SCIENCES INC
3.72%
BRIDGEBIO PHARMA INC
3.55%
REVOLUTION MEDICINES INC
3.54%
GILEAD SCIENCES INC
3.45%
UNITEDHEALTH GROUP INC
3.35%
ASTRAZENECA PLC
3.22%
Country Breakdown
United States
78.36%Switzerland
7.99%Denmark
3.66%United Kingdom
3.22%Others
6.77%Industry Breakdown
Health Care
99.62%Cash & Cash Equivalents
0.38%ETF Characteristics
As of October 29, 2026
Return on Equity
Measures how efficiently companies generate profit relative to shareholder equity. Calculated as aggregated earnings divided by aggregated average book value over the year.
18.8%
Median Market Cap
The midpoint market capitalization among all companies held in the ETF. Half of the holdings have a market cap above this figure, and half below. It gives a snapshot of the typical company size in the fund, without being skewed by a few very large or very small positions.
$
62,681
M
Price-to-Earnings (P/E)
The aggregated price of the ETF's holdings divided by aggregated expected earnings of holdings.
28.8x
Price-to-Book Value (P/BV)
The aggregated price of the ETF's holdings divided by aggregated forecast book value of holdings.
4.9x
Price-to-Sales (P/S)
The aggregated price of the ETF's holdings divided by aggregated expected sales of holdings.
2.4x
Risk Statistics
As of September 30, 2026
Beta vs. S&P 500
Measures how the ETF's daily returns move relative to stated index (S&P 500). A beta of one means it moved one for one. This measure is a one-year raw beta.
0.44
Beta vs. Nasdaq 100
Measures how the ETF's daily returns move relative to stated index (Nasdaq 100). A beta of one means it moved one for one. This measure is a one-year raw beta.
0.13
Beta vs. MSCI-EAFE
Measures how the ETF's daily returns move relative to stated index (MSCI EAFE). A beta of one means it moved one for one. This measure is a one-year raw beta.
0.47
Beta vs. MSCI Emg. Mkts.
Measures how the ETF's daily returns move relative to stated index (MSCI Emerging Markets). A beta of one means it moved one for one. This measure is a one-year raw beta.
0.11
Standard Deviation
An annualized measure of how much the ETF's daily total returns have varied over the past year.
16.20%
- Performance
- Distributions
- Premium / Discount
Prices & Performance
{id=226085095982, createdAt=1793408446791, updatedAt=1793408446791, 2='{type=list, value=[{id=134582761143, name='Heart & Health ETF'}]}', 3='{type=string, value=NAV}', 4='{type=number, value=6.0E-4}', 5='{type=number, value=0.0271}', 6='{type=number, value=0.1892}', 9='{type=number, value=0.1275}', 10='{type=number, value=1790726400000}', 11='{type=string, value=M}'}
As of
Sep 30, 2026
- Sep 30, 2026
- Sep 30, 2026
HRTS
3 months
1 Year
3 Years
5 Years
Since inception
NAV
0.06%
0.06%
18.92%
18.92%
12.75%
12.75%
Market Price
0.11%
0.11%
18.94%
18.94%
12.80%
12.80%
Performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance data quoted. Returns for periods of less than one year are not annualized.
The market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share, and do not represent the returns you would receive if you traded shares at other times. NAVs are calculated using prices as of 4:00 PM Eastern Time. The first trading date is typically several days after the fund inception date. Therefore, NAV is used to calculate market returns prior to the first trade date because there is no bid/ask spread until the fund starts trading.
Distributions
Record Date
Ex-Date
Payable Date
Total Distribution
Income
Dec 11, 2024
Dec 11, 2024
Dec 12, 2024
$0.46931283
$0.14290283
Dec 10, 2025
Dec 10, 2025
Dec 11, 2025
$0.47290596
$0.47290596
-0.11
-0.01
0.07
-0.08
-0.08
-0.03
-0.03
0.01
-0.04
-0.09
0.01
-0.06
-0.11
-0.04
0.01
0.06
-0.07
-0.05
0.04
0.01
-0.07
0
-0.17
-0.24
Premium/Discount
Сhart
Table
Days Traded at Nav
Days Traded at Premium
Days Traded at Discount
2023/Q4
2
26
0
2024/Q1
0
57
4
2024/Q2
0
51
12
2024/Q3
1
45
18
2024/Q4
1
23
40
2025/Q1
2
9
50
2025/Q2
1
17
44
2025/Q3
0
4
60
2025/Q4
1
2
61
2026/Q1
0
22
39
2026/Q2
2
16
44
2026/Q3
3
29
32
HRTS NAV / Market Price
NAV$38.58
Daily Change
$0.84
2.23%
Market Price$38.54
Daily Change
$0.80
2.12%
Premium/Discount-0.11%
30-Day Median Bid/Ask Spread 0.34%
As of October 29, 2026
October-26
September-26
August-26
July-26
June-26
May-26
April-26
March-26
February-26
January-26
December-25
November-25
October-25
Investment Partner
David K. Song, MD, PhD, CFA
David Song is the Head of Healthcare and Investment Partner at Tema ETFs. David has led biotechnology and healthcare investment teams throughout his extensive 25-year career at Rockefeller Capital Management, Millennium and Balyasny. He studied Economics and Biochemistry at Yale, is a medical doctor and has a PhD in Applied Economics from Wharton. David is a CFA charter holder.
How to buy
.svg){kind=small}
*Neither Tema ETFs LLC nor undefined ETF are affiliated with these financial services firms. Their listing should not be viewed as a recommendation or endorsement.
Latest Research & Insights
Stay informed with our latest research, insights, and market analysis to make better investment decisions.
The AI Drug Discovery Revolution
Explore how AI is turning drug discovery into more of an engineering discipline capable of unlocking more treatments and value for patients and healthcare.
Why Healthcare Is Worth Revisiting as 2026 Draws to a Close
Explore why healthcare investments are becoming increasingly attractive as market ownership hits historic lows, despite strong growth and innovation prospects.
What to Expect When You’re Expecting… A Mid-Term Election
Learn what the 2026 midterms could mean for AI regulation, U.S. manufacturing, healthcare, and the investment opportunities that follow.
Subscribe for Updates
Risk Information
Carefully consider the Fund’s investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Fund’s prospectus or summary prospectus, which may be obtained by visiting www.temaetfs.com. Read the prospectus carefully before investing.
On 06/27/2025 the Tema GLP-1, Obesity & Cardiometabolic ETF was renamed Tema Heart & Health ETF. Investing involves risk including possible loss of principal. There is no guarantee the adviser’s investment strategy will be successful.
Industry Concentration Risk: Because the Fund's assets will be concentrated in an industry or group of industries, the Fund is subject to loss due to adverse occurrences that may affect that industry or group of industries.
Biotechnology Industry Risk: The biotechnology industry can be significantly affected by patent considerations, including the termination of patent protections for products, intense competition both domestically and internationally, rapid technological change and obsolescence, government regulation and expensive insurance costs due to the risk of product liability lawsuits. In addition, the biotechnology industry is an emerging growth industry, and therefore biotechnology companies may be thinly capitalized and more volatile than companies with greater capitalizations.
Sector Focus Risk: Obesity and Cardiology companies are highly dependent on the development, procurement and marketing of drugs and the protection and exploitation of intellectual property rights. A company’s valuation can also be greatly affected if one of its products is proven or alleged to be unsafe, ineffective or unprofitable. The stock prices of Obesity and Cardiology companies have been and will likely continue to be very volatile. The costs associated with developing new drugs can be significant, and the results are unpredictable.
Newly developed drugs may be susceptible to product obsolescence due to intense competition from new products and less costly generic products. Moreover, the process for obtaining regulatory approval by the U.S. Food and Drug Administration or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals will be obtained or maintained. Companies in the medical equipment industry group may be affected by the expiration of patents, litigation based on product liability, industry competition, product obsolescence and regulatory approvals, among other factors.
Investing in foreign and emerging markets involves risks relating to political, economic, or regulatory conditions not associated with investments in U.S. securities and instruments. In addition, the fund is exposed to currency risk.
Because the Funds evaluate ESG factors to assess and exclude certain investments for non-financial reasons, the Funds may forego some market opportunities available to funds that do not use these ESG factors.
Tema ETFs LLC serves as the investment adviser to Tema Heart & Health ETF (the “Fund”), and Tidal Investments LLC serves as a sub adviser to the Fund. The Fund is distributed by Vigilant Distributors, LLC, which is not affiliated with Tema ETFs LLC nor Tidal Investments LLC. Check the background of Vigilant Distributors, LLC on FINRA’s BrokerCheck.